PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).Lauren C. Harshman, Brian Shuch, Toni K. Choueiri et al.|Journal of Clinical Oncology|2019Cited by 13
PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).Mohamad E. Allaf, Naomi B. Haas, Se Eun Kim et al.|Journal of Clinical Oncology|2021Cited by 10
PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).Naomi B. Haas, Michael A. Carducci, Mäneka Puligandla et al.|Journal of Clinical Oncology|2020Cited by 8
PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).Lauren C. Harshman, Mäneka Puligandla, Naomi B. Haas et al.|Journal of Clinical Oncology|2019Cited by 7
PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).Lauren C. Harshman, Mäneka Puligandla, Mohamad E. Allaf et al.|Journal of Clinical Oncology|2020Cited by 2